Treatment options for older patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are limited and the prognosis remains poor, thereby warranting development of novel therapies. Aberrant epigenetic modifications, including altered DNA methylation, seem to contribute to the pathogenesis of these patients. In fact, hypomethylating agents (HMA) like azacitidine have been successfully used in clinical trials and achieved approval from health authorities. There is now growing evidence suggesting that the combination of drugs with different mechanisms of action might offer a potential benefit to these patients. This is especially done with the intention to synergize the positive effects of each drug on the defective hematopoiesis while sparing potential side effects and toxicities. Combination of HMA with histone deacetylase inhibitors, although mechanistically very tempting, have not yielded convincing improvement of the results in the majority of trials compared to single agent HMA treatment. Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them an appealing option for treatment in these patients.
INTRODUCTION
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal disorders of hematopoietic stem cells leading to clonal expansion and ineffective hematopoiesis clinically resulting in anemia, bleeding and infections. Higher-risk MDS subtypes are commonly defined as patients with excess of myeloblasts and/or dismal chromosomal aberrations and/or severe cytopenias. These findings are reflected by International Prognostic Scoring System (IPSS) risk score 41.0. Patients with higher-risk MDS offered only supportive care often experience rapid disease progression towards AML and often face a life expectancy of less than 1 year. Allogeneic hematopoietic stem cell transplantation remains the only potentially curative option, however, in most cases, is not considered because the majority of these patients are in their 7th decade of life at diagnosis. 1 Therefore, recent non-intensive therapeutic developments include hypomethylating agents (HMA) such as azacitidine and decitabine, which can nowadays be considered the backbone of treatment in many patients with higher-risk MDS or AML. 2 Although both drugs seem to have a rather comparable mode of action, several randomized clinical trials with decitabine, in contrast to azacitdine, have not convincingly shown a survival benefit compared to standard treatment in these patients. 3, 4 Further, lenalidomide is predominantly active in del(5q) lower-risk MDS patients (IPSSp1.0) 5 while a recent study clearly demonstrated that the drug does not promote disease progression. 6 This review will focus on the rationale and therapeutic potential to combine azacitidine with lenalidomide in patients with MDS or AML.
ACTIVITY OF SINGLE-AGENT AZACITIDINE IN MDS OR AML
Azacitidine (Vidaza), an analog of the pyrimidine nucleoside cytidine, exerts modulating effects on the differentiation of cells, their gene expression, DNA synthesis and metabolism, respectively. By binding to DNA methyltransferase, the latter is inhibited during DNA replication, accompanied by reduced methylation of certain genes. 7 Azacitidine is primarily incorporated into RNA and thus also inhibits the translation of proteins. The substance became known in the 1970s and, at the beginning, was used at higher doses than today to treat AML patients. Later, data, although not very encouraging at the beginning, 8 were obtained with lower doses, which seemed to have a better effect in patients with AML or MDS. Hereby, the modulating properties of the substance on methyltransferase activity were observed and thus on the modulation of gene expression. The increased methylation of so-called CpG islands of DNA is a common mechanism of neoplastic cells, which prevents the expression of critical tumor suppressor genes, and permits tumor cell proliferation. This phenomenon has been described very often in both MDS and AML [9] [10] [11] and azacitidine exerts its effects at least in part through randomly inducing re-expression of these genes. [12] [13] [14] Different studies using single agent azacitidine have been concluded in all subtypes of MDS. 7, 15 In IPSS, high and int-2 risk MDS with up to 30% bone marrow blasts, administration of azacitidine as a stand-alone therapy can improve survival over conventional treatments including best supportive care only, lowdose cytarabine or induction chemotherapy. In fact, in the AZA-001 trial remission rates comprised 49% of treated patients with an improvement of blood counts (hematologic improvement (HI) according to IWG criteria) including 29% of patients with either complete remission (CR) or partial remission resulting in a significant survival benefit (median overall survival 24 vs 15 months) for the azacitidine-treated patients. 2 Meanwhile, a trial with a comparable study design has been initiated for older patients with AML and more than 30% bone marrow blasts (NCT01074047). It will be interesting to see whether the benefit of single-agent azacitidine continues to be apparent across a certain blast threshold. The current available data suggest comparable response rates in newly diagnosed patients with AML 16, 17 even allowing outpatient treatment. This clearly proves the antileukemic effect of the substance, which might be, although not with a curative attempt, an interesting alternative to conventional chemotherapy, mainly in older patients with higher-risk MDS and AML patients. Nevertheless, current data supporting the use of azacitidine in AML are limited to retrospective studies or small clinical trials and should therefore be interpreted with caution.
In patients with MDS or AML and up to 30% of blasts, initial hematologic responses seem to occur independently of cytogenetic risk groups including patients with complex abnormalities. 18 However, poor-risk cytogenetic abnormalities were associated with lower survival rates compared to other cytogenetic abnormalities, even in cases when del(5q) was part of a complex abnormal karyotype often harboring additional TP53 mutations. 2, 18, 19 In fact, recent data have also confirmed that the presence of a TP53 mutation per se is not associated with a lower probability to respond to single-agent azacitidine therapy. 19 Azacitidine is not only active in higher-risk disease but comparable response rates have been observed also in IPSS low/Int-1 patients including those with a del(5q) abnormality. 20 A recent abstract by the GFM group demonstrated in a limited number of patients that single-agent azacitidine therapy was active (CR, partial remission, HI) in 5 out 13 patients (39%) with del(5q) MDS IPSS low/Int-1 after failing therapy with lenalidomide, although the majority had progressed to a higher IPSS stage already. 21 Several trials have been published aiming at improvement of responses with single-agent azacitidine including combinations with valproic acid as well as newly-developed histone deacetylase inhibitors. 22 However, there is currently no formal proof from a randomized study that any of these combinations might lead to an improvement of responses and survival compared to singleagent therapy. 23 
ACTIVITY OF SINGLE-AGENT LENALIDOMIDE IN MDS OR AML
Lenalidomide (Revlimid) belongs to a proprietary class of compounds called immunomodulatory derivatives (IMiDs). IMiDs, of which thalidomide is the parent compound, have immunomodulatory and anti-angiogenic properties and confer broad antitumor and anti-metastatic effects. Although the mode of action is, still, incompletely understood, lenalidomide has been demonstrated to possess anti-angiogenic activity through inhibition of bFGF, VEGF and TNF-alpha induced endothelial cell migration. 24 In addition, lenalidomide has a variety of immunomodulatory effects. It stimulates T-cell proliferation, and the production of for example, IL-2, inhibits IL-1 beta and IL-6 and modulates IL-12 production. 25, 26 Lenalidomide has shown high-response rates predominantly in red blood cell-transfusion dependent MDS patients with IPSSdefined low-or int-1 risk and del(5q). 5 Experimental evidence suggests that abnormal erythroid differentiation and apoptosis in del(5q) disease is caused by haploinsufficiency of the ribosomal subunit 14 gene, RPS14. 27 This interferes with normal ribosomal biosynthesis and leads to high levels of free ribosomal proteins in the cell, which bind to human homolog of murine double minute 2 (MDM2), a negative regulator of p53, leading to its ubiquitination and degradation. This, in turn, leads to an accumulation of p53 and drives apoptosis in erythroid progenitor cells. It has also been shown that lenalidomide inhibits the CDC25C phosphatase, leading to inhibition of PP2A and subsequent stabilization of MDM2, which in turn promotes p53 degradation. 28 Lenalidomide also restores erythroid differentiation 29 and expression of microRNAs, which are involved in the regulation of the innate immune system and are found to be underexpressed in CD34 þ cells from patients with del(5q) MDS. Knockout mice lacking these molecules exhibited variable neutropenia, hypolobulated megakaryocytes and suppressed myeloid progenitor activity in the bone marrow. 30 Lenalidomide often has a potent 'myeloablative' effect during the first cycles of treatment that goes along with the effective elimination of del(5q) clonal myeloid progenitors. 31 Therefore, cytopenia is a frequent event soon after initiation of the therapy and has been associated, in contrast to non-del(5q) MDS, with treatment response. 32 Once the del(5q) clone has been effectively eliminated, the bone marrow is repopulated with lineages derived from a small number of normal CD34 þ progenitors that are spared by the drug, although the clonal progenitor cells seem to persist at a low frequency. 33 Nevertheless, the drug is active, but to a lesser extent, in non-del(5q) MDS. Unlike in the del(5q) MDS studies, significant myelosuppression occurs in only one quarter of patients and does not predict response to therapy. This, coupled with findings from several in vitro studies, fosters the argument that for del(5q) patients, lenalidomide appears to have a direct, cytotoxic effect on the dysplastic clone; whereas for lower-risk MDS patients without the del (5q) abnormality, lenalidomide's clinical benefits appear to be mediated through various effects including direct 'stimulation' of healthy progenitors 34 as well as modulation of the bone marrow microenvironment. 35 In the MDS-002 trial in 214 patients with low to int-1 risk, MDS not harboring a del(5q) transfusion independence was achieved in roughly one quarter of patients after a median of 4.8 weeks of treatment with a median duration of transfusion independence of 41.0 weeks. 36 The most common grade 3-4 adverse events were neutropenia (30%) and thrombocytopenia (25%). This also shows that grade 3-4 leukopenia and thrombocytopenia occur almost two times more frequently in patients with del(5q) than in those patients harboring other abnormalities again decisively demonstrating the enhanced sensitivity of del(5q) progenitors to the action of lenalidomide.
In a multicenter trial (MDS-003) in 148 MDS patients with a clonal interstitial deletion involving chromosome 5q, lenalidomide was given at a dose of 10 mg on days 1-21, repeated every 28 days, to 44 patients, and at a dose of 10 mg daily to the other 104 patients. Transfusion independence was achieved in 93 patients (64%), with a median hemoglobin increase of 3.9 g/dl. Pathologic complete response was documented in 32 out of 110 (29%) evaluable patients. With a median follow-up of 9.3 months, the median response duration had not been reached. Grade 3-4 neutropenia (B50%) and thrombocytopenia (B50%) were the most common adverse events requiring dose delays or reductions. 37 Cytogenetic response was achieved in 76% of transfusionindependent patients with 55% achieving a complete cytogenetic response. Thrombocytopenia and high transfusion requirements, prior to administration of lenalidomide, were the only negative predictive factors for response, whereas FAB category was not. The results in lower-risk del(5q) MDS patients were confirmed recently within the MDS-004 study 38 but with a lower complete cytogenetic rate of 29% compared to the previous reports, which might be explained by different patient characteristics and the great heterogeneity of this rare subtype of MDS. Interestingly, complete cytogenetic remissions were also, although infrequently, observed in some patients with complex karyotype including other abnormalities suggesting a 'leading' position of del(5q) in subgroups of complex cytogenetic aberrations. This is in agreement with other reports 39, 40 and suggests finally a Azacitidine and lenalidomide in MDS or AML U Platzbecker et al therapeutic role of lenalidomide in this group of patients with otherwise dismal outcome. Additionally, lenalidomide has been shown to be active as a single agent even in patients with higherrisk MDS and a del(5q), [41] [42] [43] although the remission rates are lower compared to lower-risk MDS, which might be at least in part mediated by additional molecular events including inactivating TP53 mutations. 44 In MDS patients, TP53 mutations and loss of 17p including the TP53 locus have been frequently found in higher-risk MDS with complex karyotype and therapy-related secondary MDS and have been associated with disease progression. 45, 46 While early studies using Sanger sequencing technology failed to identify TP53 mutations in lower-risk MDS patients, recent data 47 using next-generation deep-sequencing (NGS) technology demonstrated TP53 mutations in a substantial proportion of MDS patients with IPSS low and int-1 disease and del(5q). In a cohort of 55 patients, 18% displayed mutated TP53 with a median clone size of 11% (range, 1-54%). All mutations affected the binding function of TP53 and all had been previously described in other tumors. Interestingly, the presence of a TP53 mutation even in a small clone size at the time of diagnosis was associated with a higher rate of leukemic evolution and, additionally, was less likely to respond to single-agent lenalidomide. In fact, the probability of a complete cytogenetic response to the drug was lower in mutated patients (0% o0 of 74 vs 50% o12 of 244; P ¼ 0.024).
The Swedish study group further demonstrated the absence of cytogenetic responses to lenalidomide in higher-risk MDS with del(5q) and a TP53 mutation. 48 Therefore, patients with a diagnosis of del(5q) MDS harboring a TP53 mutation should be considered a distinct class requiring different treatment strategies, for example, involving combinations of lenalidomide with HMA, like azacitidine, which seem to be active irrespective of TP53 mutation status 19, 49 Lenalidomide has been used in the treatment of patients with higher-risk MDS or AML as a single agent as well. A critical comment published by Steensma and Stone 50 sums up that despite promising results in a subset of patients harboring the del(5q), 51, 52 the impressive clinical benefit that is seen in lower-risk del(5q) MDS has not been achieved in higher-risk patient classes. The main reason for this fact is very likely related to a different pathophysiology of lower-risk vs higher-risk MDS as well as AML, namely different break point regions on chromosome 5q, additional genetic events (for example, mutations) and the drastic expansion of blasts not responding to any non-cytotoxic compound.
Nevertheless, it is noteworthy, that in clinical studies 51, 52 14 and 30% respectively of the treated patients achieved at least a partial remission, demonstrating a modest activity of lenalidomide as first-line treatment in AML patients. Harboring the del(5q) aberration was not necessarily associated with response. Of interest, Fehninger et al. 53 reported on activity of lenalidomide in 2 AML patients with trisomy 13, indicating that there are specific effects of the drug independent of del(5q). Case reports on lenalidomide in relapsed patients with AML and del(5q) after allogeneic hematopoietic stem cell transplantation demonstrated a potential benefit in such patients. 42, 54, 55 Nevertheless, a recent phase 2 study in MDS and AML patients with del(5q) was terminated prematurely because of graft versus host disease (GVHD) induction when lenalidomide was given as maintenance treatment. 56 
RATIONALE FOR THE COMBINATION OF AZACITIDINE AND LENALIDOMIDE
The basic rationale to combine both agents is supported by reasonable single-agent activities across all stages of MDS and AML irrespective of their different and obviously not overlapping mode of action. Although not formally proven, one might speculate that higher-risk MDS subtypes retain specific disease properties of lower-risk MDS making them also susceptible to combination therapies, which include lenalidomide. Most importantly, there is a paucity of effective drugs for these patients, which are well tolerable in terms of acceptable side effects. In fact, one might speculate that the cumulative hematological toxicity might be the only clinical limitation of such a combination. As the effects of azacitidine are dependent on cycling cells and lenalidomide inhibits cell cycle progression, 44, 49 the rather sequential administration of azacitidine followed by lenalidomide may maximize their additive effects. The preclinical and clinical data available so far suggest a best synergistic effect of both compounds, especially for patients with del(5q) disease (Figure 1 ).
CLINICAL TRIALS WITH COMBINED AZACITIDINE AND LENALIDOMIDE IN MDS OR AML
Current published studies on the combination of both agents are summarized in Tables 1 and 2 , respectively. The first study exploring a combination of azacitidine and lenalidomide was performed by Sekeres et al. 57 using a concomitant approach of 5 days of standard doses of azacitidine and different schedules of lenalidomide. In fact, within the phase 1 part of the study, the authors could identify lenalidomide for 21 days at a dose of 10 mg daily as the maximum tolerated dose within this combination. It is of note that the results suggested a synergistic effect with regards to response, while hematological toxicity did not seem to be potentiated compared to single-agent therapy. Subsequently, this regimen was explored in a phase-2 study in a larger cohort of patients mostly with higher-risk MDS and normal karyotype. In this study, a response rate of 72% including 44% with a CR (compared to 49 and 17% with azacitidine alone) was reported. 58 The median (Platzbecker et al, 2013) overall: 26% untreated: 44% (1-6) 2 Abbreviations: Aza, azacitidine; c, cohort; CR, complete remission; CRi, CR with incomplete recovery of peripheral blood counts; Len, lenalidomide; PR, partial response.
Azacitidine and lenalidomide in MDS or AML U Platzbecker et al survival for the entire population was shorter than in the AZA-001 study, 2 at 13.6 months compared with 24.5 months potentially as a result of a shorter median followup (11.5 months vs 21.1 months), different patient populations and the study design, which allowed continuation of azacitidine only after six cycles of combined treatment. Notably, median survival for patients with CR was more than 3 years. Complete cytogenetic responses were reported in 30% of patients, however, most of the patients displayed a normal karyotype. Interestingly, mutational status of genes such as TET2 and DNMT3A was associated with response in a limited number of patients. In this trial, no responses were observed in patients with complex cytogenetic abnormalities. 58 The synergistic activity of the combination is further supported by a follow-up report of this trial, in which three patients who achieved a CR within the combination therapy time period then continued on azacitidine monotherapy for several months before relapsing with cytopenias and excess blasts. They all regained their remission solely with the re-initiation of lenalidomide combined with their continuation of azacitidine therapy. 59 Meanwhile, three independent phase-I studies have demonstrated the potential of combining azacitidine and lenalidomide in higher risk but mostly, non-del(5q) MDS or AML. 49, [60] [61] [62] The data from the first phase-I trial in del(5q) higher-risk MDS or AML patients demonstrated that sequential treatment with azacitidine (5 days) followed by lenalidomide (14 days) is also feasible and potentially effective. The primary objective of this phase-I study was to identify the dose-limiting toxicity (DLT) and maximum tolerated dose of this sequential combination in patients with higher risk de novo or relapsed/refractory MDS or AML and del(5q). However, the maximum tolerated dose of lenalidomide in combination with azacitidine at the schedule reported was lower (20 mg) than in other reports. 49, 57 The AE profile of sequential azacitidine and lenalidomide was consistent with that of the individual drugs; thrombocytopenia and neutropenia were the most common treatment-related AEs. The same is true for other studies investigating either concomitant 58, 61 or sequential treatment. 62, 63 However, the delayed recovery of blood counts, even in the presence of a hematological and cytogenetic response, demonstrates the impressive and sustained general cytoreductive potential of this combination in del(5q) disease. Further, in our study (AZALE-trial), more heavily pretreated patients (also those with prior azacitidine or lenalidomide treatment) and the sequential approach might have potentiated the hematological toxicity profile of both compounds. The hematological toxicity reported so far in other combinations trials mostly with patients lacking del(5q) appears to be lower than with our approach. 58, [61] [62] [63] Also, myelosuppression is more common in lenalidomide-treated del(5q) MDS patients since progenitor cells with del(5q) are more sensitive to lenalidomide than those with other cytogenetic abnormalities. 33, 64 Overall, hematological response rates in all published combination studies among previously untreated patients are encouraging considering the population's higher risk and low number of treatment cycles needed, which appear comparable to data with azacitidine alone with a median of nine cycles administered. 2 In fact, in most of the studies, responses were obtained very rapidly, although sometimes at the expense of toxicity. Impressive and early response rates 63 with a concomitant approach (mostly azacitidine days 1-5, 10 mg lenalidomide days 1-21) have been reported in six out of eight previously untreated patients with MDS or AML. Notably, all patients had either del(5q) or monosomy 5 embedded into a complex karyoytpe. Initial responses occurred early at a median of 10 weeks (range, 6-28 weeks) from the beginning of therapy. With a median followup of 60 weeks for the responding patients, (range, 0-72), four of the six responding patients relapsed at a median of 12 weeks (range, 8-36 weeks) from initial response while two patients are in an ongoing CR after being consolidated by an allogeneic hematopoietic stem cell transplantation. Preliminary data from another phase-I trial of sequential azacitidine 75 mg/m 2 /day and lenalidomide 10-75 mg in higher-risk MDS or AML patients showed that three of five previously untreated patients achieved a CR compared with no responses in previously treated patients. 65 In this study, none of the patients had complex cytogenetics (eight patients had normal cytogenetics and eight had del[5q]). In contrast, in our study and the study by Scherman et al. 63 , all patients had del(5q), with the majority (80%) associated with complex cytogenetics, and 11 patients additionally had up to 3 different TP53 mutations at baseline. Aberrant activation of the TP53 tumor-suppressor pathway underlies MDS pathophysiology in some patients with del(5q). 47, 66 Using a sensitive deep-sequencing approach, we found that the TP53 clone can be targeted after just one cycle of sequential azacitidine and lenalidomide therapy. We observed a decrease and even disappearance of the TP53 mutations in patients achieving complete cytogenetic response and hematological remission. This effect was not reported with lenalidomide alone, which suggests the potential benefit of its combination with azacitidine in these patients. In fact, both lowerand higher-risk del(5q) MDS patients harboring a TP53 mutation have a lower response rate to lenalidomide and a high risk of AML evolution compared to unmutated patients. 47 Whether the addition of azacitidine might improve treatment outcome needs to be evaluated in future studies. In fact, there is a scientific rationale to combine both azacitidine and lenalidomide in lowerrisk (IPSS low/Int-1) MDS with del(5q) and TP53 mutation to interfere with the natural course of the disease in both lenalidomide-naive and -resistant patients.
In another phase-1 study of sequential azacitidine 75 mg/m 2 and lenalidomide up to 50 mg in previously untreated elderly patients with non-del(5q) AML, the maximum tolerated dose was not reached in this combination. 60 The high response rate of rate of 44% in this study with a mean of 2.5 cycles to achieve best response, may be also explained by the comparatively low percentage (31%) of patients with adverse baseline cytogenetics. In the subsequent phase 2 part, the authors reported an overall response rate of 41% (CR ¼ 19%, CRi ¼ 9% and partial remission ¼ 12%). 62 The median time to response was 6 and 12 weeks, respectively, for patients with either CR or partial remission. Interestingly, there was no association with cytogenetics and initial response with CR even in patients with complex karyotypes, although the survival differed between risk groups.
A different phase 1 prospective trial of concomitant azacitidine and high-dose lenalidomide followed by maintenance therapy with standard dose azacitidine and lower dose of lenalidomide was recently administered in AML patients mostly (42%) with normal karyotype. 61 In contrast to Pollyea et al. 60 , this group used escalating doses of azacitidine (25 mg/m 2 , 50 mg/m 2 ; 75 mg/m 2 ) while keeping the lenalidomide dose (50 mg on days 1-28) constant and reduced the dose of lenalidomide (10 mg/day) after the initial two cycles of therapy. Again, no DLT could be defined. The most common 3/4 non-DLT hematological toxicity was thrombocytopenia seen in 10 (76.9%) out of 13 patients. Of the 13 evaluable patients, 7 (53.8%) responded to treatment, with CR/ CRi in 4 (30.8%) and partial remission in 3 (23.1%), with a median duration of response of 3 months (range 1-17).
CONCLUDING REMARKS
The published data on the combination of azacitidine and lenalidomide in higher-risk MDS or AML patients have shown the general feasibility and tolerability of this approach with lenalidomide doses of up to 50 mg daily being delivered in addition to standard doses of azacitidine without major toxicities except for neutropenia and thrombocytopenia. The initial responses seem to be achieved earlier and overall response rates higher than with single-agent azacitidine treatment, although many patients lost their responses quite early during treatment. Ongoing (for example, NCT01522976) and future randomized studies will have to investigate the role of such combinations in patients with higher-risk MDS or AML.
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